Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 1, 2012, Pages 31-38

  Undre, N ^a   Stevenson, P ^b   Baraldi, E ^c  

^a ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^b Astellas Pharma GmbH   (Germany)

^c Embassy Drive Medical Center ^*  (South Africa)

Author keywords

Esophageal candidiasis; Human immunodeficiency virus; Micafungin; Pharmacokinetic

Indexed keywords

MICAFUNGIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ESOPHAGOSCOPY; ESOPHAGUS CANDIDIASIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEGRO; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PREDICTION; PROSPECTIVE STUDY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHINOCANDINS; ESOPHAGEAL DISEASES; ESOPHAGOSCOPY; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857654811     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0063-8     Document Type: Article

References (25)

1. DR Andes DJ Diekema MA Pfaller K Marchillo J Bohrmueller 2008 In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model Antimicrob Agents Chemother 52 10 3497 3503 18625768 10.1128/AAC.00478-08 1:CAS:528: DC%2BD1cXht1SrtbjI
2. Astellas Pharma GmbH (2008) Mycamine: summary of product characteristics [accessed 18 June 2009]
3. G Barbaro G Barbarini G Di Lorenzo 1996 Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group Chest 110 6 1507 1514 8989069 10.1378/chest.110.6.1507 1:CAS:528:DyaK2sXit1aksr8%3D
4. DK Benjamin Jr PB Smith A Arrieta L Castro PJ Sánchez D Kaufman LJ Arnold LL Kovanda T Sawamoto DN Buell WW Hope TJ Walsh 2010 Safety and pharmacokinetics of repeat-dose micafungin in young infants Clin Pharmacol Ther 87 1 93 99 19890251 10.1038/clpt.2009.200
5. N de Wet A Llanos-Cuentas J Suleiman E Baraldi EF Krantz M Della Negra H Diekmann-Berndt 2004 A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients Clin Infect Dis 39 6 842 849 15472817 10.1086/423377 (Pubitemid 39244300)
6. Freire A, Arrieta A, Stevenson P, Undre N (2007) Pharmacokinetics of Micafungin in pediatric patients with invasive candidiasis and candidemia. Paper presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007
7. T Gumbo GL Drusano W Liu RW Kulawy C Fregeau V Hsu A Louie 2007 Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Antimicrob Agents Chemother 51 3 968 974 17194830 10.1128/AAC.01337-06 1:CAS:528:DC%2BD2sXis12js7s%3D (Pubitemid 46355282)
8. MF Hebert DK Blough RW Townsend M Allison D Buell J Keirns I Bekersky 2005 Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 9 1018 1024 16100295 10.1177/0091270005279274 1:CAS:528:DC%2BD2MXhtVemsrnM (Pubitemid 41192360)
9. MF Hebert HE Smith TC Marbury SK Swan WB Smith RW Townsend D Buell J Keirns I Bekersky 2005 Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction J Clin Pharmacol 45 10 1145 1152 16172179 10.1177/0091270005279580 1:CAS:528:DC%2BD2MXhtFeqsrfF (Pubitemid 41361914)
10. J Hiemenz P Cagnoni D Simpson S Devine N Chao J Keirns W Lau D Facklam D Buell 2005 Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant Antimicrob Agents Chemother 49 4 1331 1336 15793107 10.1128/AAC.49.4.1331-1336.2005 1:CAS:528:DC%2BD2MXjt1Gjsrs%3D (Pubitemid 40463357)
11. JE Kaplan D Hanson MS Dworkin T Frederick J Bertolli ML Lindegren S Holmberg JL Jones 2000 Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy Clin Infect Dis 30 Suppl 1 S5 S14 10770911 10.1086/313843
12. JE Kaplan C Benson KH Holmes JT Brooks A Pau H Masur 2009 Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America MMWR Recomm Rep 58 RR-4 1 207
13. Kuse E, Demeyer I, Stevenson P, N Undre N (2007a) Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Paper presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007
14. ER Kuse P Chetchotisakd CA da Cunha M Ruhnke C Barrios D Raghunadharao JS Sekhon A Freire V Ramasubramanian I Demeyer M Nucci A Leelarasamee F Jacobs J Decruyenaere D Pittet AJ Ullmann L Ostrosky-Zeichner O Lortholary S Koblinger H Diekmann-Berndt OA Cornely 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 9572 1519 1527 17482982 10.1016/S0140-6736(07)60605-9 1:CAS:528:DC%2BD2sXkvFGmt7c%3D (Pubitemid 46670281)
15. S Maesaki MA Hossain Y Miyazaki K Tomono T Tashiro S Kohno 2000 Efficacy of FK463, a (1, 3)-beta-d-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice Antimicrob Agents Chemother 44 6 1728 1730 10817741 10.1128/AAC.44.6.1728-1730.2000 1:CAS:528: DC%2BD3cXjs1OlsLY%3D (Pubitemid 30340827)
16. R Manfredi S Sabbatani L Calza 2007 Recurring Candida albicans esophagitis in a HIV-infected patient undergoing long-Term antiretroviral therapy, and with absent-negligible immunodeficiency Brazilian J Infect Dis 11 605 609 10.1590/S1413-86702007000600016 (Pubitemid 351425845)
17. SA Messer DJ Diekema L Boyken S Tendolkar RJ Hollis MA Pfaller 2006 Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp J Clin Microbiol 44 2 324 326 16455878 10.1128/JCM.44.2.324-326.2006 1:CAS:528:DC%2BD28XitFShtLg%3D (Pubitemid 43222217)
18. PG Pappas CM Rotstein RF Betts M Nucci D Talwar JJ De Waele JA Vazquez BF Dupont DL Horn L Ostrosky-Zeichner AC Reboli B Suh R Digumarti C Wu LL Kovanda LJ Arnold DN Buell 2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 7 883 893 17806055 10.1086/520980 1:CAS:528:DC%2BD2sXhtFOntr7I (Pubitemid 47580382)
19. MA Pfaller L Boyken RJ Hollis J Kroeger SA Messer S Tendolkar DJ Diekema 2008 In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance J Clin Microbiol 46 1 150 156 18032613 10.1128/JCM.01901-07 1:CAS:528: DC%2BD1cXhs1aqtb8%3D
20. K Tabata M Katashima A Kawamura A Kagayama S Kohno 2006 Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis Eur J Drug Metab Pharmacokinet 31 2 123 128 16898081 10.1007/BF03191129 1:CAS:528:DC%2BD28XnslOrt78%3D (Pubitemid 44166291)
21. K Tabata M Katashima A Kawamura Y Tanigawara K Sunagawa 2006 Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections Biol Pharm Bull 29 8 1706 1711 16880629 10.1248/bpb.29.1706 1:CAS:528:DC%2BD28XhtVWgsrvM (Pubitemid 44166376)
22. KB Tong KN Murtagh C Lau R Seifeldin 2008 The impact of esophageal candidiasis on hospital charges and costs across patient subgroups Curr Med Res Opin 24 1 167 174 18036287 10.1185/030079908X253401 (Pubitemid 351160250)
23. PA Warn A Sharp G Morrissey DW Denning 2002 In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis J Antimicrob Chemother 50 6 1071 1074 12461036 10.1093/jac/dkf247 1:CAS:528:DC%2BD38XptlOitrk%3D (Pubitemid 36032834)
24. AL Werneck-Silva IB Prado 2009 Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients World J Gastroenterol 15 9 1050 1056 19266596 10.3748/wjg.15.1050
25. Yamato Y, Kaneko H, Tanimoto K, Katashima M, Ishibashi K, Kawamura A, Terakawa M, Kagayama A (2002) Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother 50 (Suppl 1):68-73 (Pubitemid 36033011)